Search
for
Sort by
Research 241–270 of 1000+
- Comparing the Efficacy of Weekly Azathioprine Pulse versus Betamethasone Oral Mini-Pulse in the Treatment of Moderate to Severe Alopecia Areata
- 724 - A phase 2b, randomized, double-blinded, parallel-group, placebo-controlled study to evaluate the efficacy and safety of rezpegaldesleukin in adults with severe to very-severe alopecia areata
- Improvement in Measures of Quality of Life and Symptoms of Anxiety and Depression in Patients with Severe Alopecia Areata Achieving Sustained Scalp Hair Regrowth with Baricitinib
- Agreement Between Patient and Physician Assessment of Eyebrow and Eyelash Hair Loss in Two Phase 3 Trials Evaluating Baricitinib in Patients with Severe Alopecia Areata
- 42736 Safety Assessments in the Multinational Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata
- MicroRNA-1246 Inhibits NFATc1 Phosphorylation and Regulates T Helper 17 Cell Activation in the Pathogenesis of Severe Alopecia Areata
- Comparative Efficacy and Adverse Clinical Events of Methotrexate versus Azathioprine with Steroid Mini Pulse Therapy in the Management of Moderate to Severe Alopecia Areata: A Tertiary Centre Based Interventional Study
- Comparison of effectiveness of weekly azathioprine pulse (WAP) and betamethasone oral mini pulse (BOMP) in the treatment of moderate to severe alopecia areata
- Efficacy of the phosphodiesterase-4 inhibitor, apremilast, in a patient with severe alopecia areata
- Ivarmacitinib for the treatment of adults with severe alopecia areata: Results from a phase 3 trial
- Efficacy, Safety, and Tolerability of Upadacitinib in Adults and Adolescents With Severe Alopecia Areata: Results From the Randomized, Placebo-Controlled, Double-Blind Phase 3 Program (UP-AA)
- Baricitinib Therapy for Moderate to Severe Alopecia Areata: A Retrospective Review of 95 Japanese Patients
- 42752 Evaluation of Eyebrow and Eyelash Regrowth and Patient Satisfaction in the Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata
- Randomized Study to Evaluate the Efficacy of Platelet Rich Plasma, Intralesional Triamcinolone Acetonide and Intralesional Normal Saline in Moderate to Severe Alopecia Areata
- Comorbid Bronchial Asthma, Atopic Dermatitis and Hashimoto's Thyroiditis Are Risk Factors for Early‐Onset, Severe and Prolonged Alopecia Areata
- 76957 Efficacy and Safety of Upadacitinib in Adolescents and Adults with Severe Alopecia Areata: A Subgroup Analysis of the UP-AA Phase 3 Clinical Program
- 74643 Deuruxolitinib improves scalp hair regrowth over time in patients with severe alopecia areata: Pooled analysis of the THRIVE-AA1 and THRIVE-AA2 Phase 3 trials
- Real-world retrospective study with upadacitinib in patients with severe alopecia areata: A series of 23 cases
- 61346 Baseline Psychosocial Impact of Disease in Patients with Severe Alopecia Areata Treated with Baricitinib Recruited from the US Customer Support Program
- Regrowth of Upper Eyelid Eyelashes After Making a Surgical Incision on the Upper Eyelid in a Case of Severe Alopecia Areata
- 73192 Consistent Efficacy of Upadacitinib in Alopecia Areata Subgroups: Adult, Pediatric, Severe Disease, and JAK-Refractory Patients — A Meta-Analysis
- 63407 A Descriptive Analysis of Patients With Moderate-to-Severe Atopic Dermatitis and Comorbid Alopecia Areata in the Abrocitinib JADE Clinical Program
- 77015 Subgroup Analysis of Efficacy of Upadacitinib in Adults and Adolescents With Severe Alopecia Areata From the UP-AA Phase 3 Program
- 74582 Early improvement in scalp hair regrowth with deuruxolitinib in patients with severe alopecia areata: Pooled analysis of the THRIVE-AA1 and THRIVE-AA2 Phase 3 trials
- P46 PSYCHOMETRIC PERFORMANCE OF EQ-5D-5L INDEX IN ADULTS AND ADOLESCENTS WITH SEVERE ALOPECIA AREATA: EVIDENCE FROM PHASE III TRIAL DATA
- Selective JAK 1 inhibition with upadacitinib as a potential treatment for coexistent severe atopic dermatitis and alopecia areata
- PCR30 PSYCHOMETRIC EVALUATION OF SKINDEX-16 AA, THE ALOPECIA AREATA SYMPTOM IMPACT SCALE (AASIS), AND THE SCALP HAIR ASSESSMENT PATIENT-REPORTED OUTCOME (PRO) IN ADULTS AND ADOLESCENTS WITH SEVERE ALOPECIA AREATA
- Publisher Correction: Improvement in Measures of Quality of Life and Symptoms of Anxiety and Depression in Patients with Severe Alopecia Areata Achieving Sustained Scalp Hair Regrowth with Baricitinib
- Public Interest in Janus Kinase (JAK) IInhibitors for Alopecia Areata: A Google Trend Analysis
- Efficacy and safety of janus kinase inhibitors in the treatment of alopecia areata in children